beam therapeutics inc. - BEAM

BEAM

Close Chg Chg %
16.67 0.32 1.92%

Open Market

16.99

+0.32 (1.92%)

Volume: 1.84M

Last Updated:

Jun 18, 2025, 4:00 PM EDT

Company Overview: beam therapeutics inc. - BEAM

BEAM Key Data

Open

$16.61

Day Range

16.18 - 17.52

52 Week Range

13.53 - 35.25

Market Cap

$1.71B

Shares Outstanding

100.56M

Public Float

89.62M

Beta

2.09

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.61

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.77M

 

BEAM Performance

1 Week
 
-0.50%
 
1 Month
 
0.86%
 
3 Months
 
-27.15%
 
1 Year
 
-26.00%
 
5 Years
 
-37.82%
 

BEAM Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 18
Full Ratings ➔

About beam therapeutics inc. - BEAM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

BEAM At a Glance

Beam Therapeutics, Inc.
238 Main Street
Cambridge, Massachusetts 02142-1016
Phone 1-857-327-8775 Revenue 63.52M
Industry Biotechnology Net Income -376,742,000.00
Sector Health Technology Employees 483
Fiscal Year-end 12 / 2025
View SEC Filings

BEAM Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 32.138
Price to Book Ratio 2.828
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.435
Enterprise Value to Sales 21.286
Total Debt to Enterprise Value 0.119

BEAM Efficiency

Revenue/Employee 131,507.246
Income Per Employee -780,004.141
Receivables Turnover N/A
Total Asset Turnover 0.05

BEAM Liquidity

Current Ratio 4.823
Quick Ratio 4.823
Cash Ratio 4.673

BEAM Profitability

Gross Margin 65.482
Operating Margin -654.252
Pretax Margin -593.065
Net Margin -593.126
Return on Assets -29.392
Return on Equity -43.938
Return on Total Capital -42.095
Return on Invested Capital -37.251

BEAM Capital Structure

Total Debt to Total Equity 22.006
Total Debt to Total Capital 18.037
Total Debt to Total Assets 14.624
Long-Term Debt to Equity 20.17
Long-Term Debt to Total Capital 16.532
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Beam Therapeutics Inc. - BEAM

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
51.84M 60.92M 377.71M 63.52M
Sales Growth
+215,916.67% +17.51% +520.01% -83.18%
Cost of Goods Sold (COGS) incl D&A
16.44M 22.58M 20.01M 21.93M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
16.44M 22.58M 20.01M 21.93M
Depreciation
16.44M 22.58M 20.01M 21.93M
Amortization of Intangibles
- - - -
-
COGS Growth
+73.57% +37.32% -11.36% +9.56%
Gross Income
35.40M 38.34M 357.70M 41.59M
Gross Income Growth
+474.71% +8.30% +832.89% -88.37%
Gross Profit Margin
+68.29% +62.94% +94.70% +65.48%
2021 2022 2023 2024 5-year trend
SG&A Expense
427.87M 376.82M 534.18M 457.16M
Research & Development
387.09M 311.59M 437.38M 367.56M
Other SG&A
40.78M 65.23M 96.80M 89.60M
SGA Growth
+246.98% -11.93% +41.76% -14.42%
Other Operating Expense
- - - -
-
Unusual Expense
(21.84M) (63.00M) 1.35M 10.23M
EBIT after Unusual Expense
(370.63M) (275.47M) (177.84M) (425.80M)
Non Operating Income/Expense
- 15.30M 46.68M 49.09M
Non-Operating Interest Income
- 15.30M 46.68M 49.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 9.00K
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 9.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(370.64M) (260.18M) (131.16M) (376.70M)
Pretax Income Growth
-90.47% +29.80% +49.59% -187.21%
Pretax Margin
-714.91% -427.08% -34.73% -593.06%
Income Tax
- 3.41M 1.37M 39.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(370.64M) (289.09M) (132.53M) (376.74M)
Minority Interest Expense
- - - -
-
Net Income
(370.64M) (289.09M) (132.53M) (376.74M)
Net Income Growth
-90.47% +22.00% +54.16% -184.28%
Net Margin Growth
-714.91% -474.54% -35.09% -593.13%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(370.64M) (289.09M) (132.53M) (376.74M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(370.64M) (289.09M) (132.53M) (376.74M)
EPS (Basic)
-5.7707 -4.1289 -1.7177 -4.5769
EPS (Basic) Growth
-37.69% +28.45% +58.40% -166.46%
Basic Shares Outstanding
64.23M 70.02M 77.15M 82.31M
EPS (Diluted)
-5.7707 -4.1289 -1.7177 -4.5769
EPS (Diluted) Growth
-37.69% +28.45% +58.40% -166.46%
Diluted Shares Outstanding
64.23M 70.02M 77.15M 82.31M
EBITDA
(376.02M) (315.90M) (156.47M) (393.64M)
EBITDA Growth
-205.00% +15.99% +50.47% -151.57%
EBITDA Margin
-725.30% -518.55% -41.43% -619.73%

Snapshot

Average Recommendation BUY Average Target Price 43.438
Number of Ratings 18 Current Quarters Estimate -1.113
FY Report Date 06 / 2025 Current Year's Estimate -4.599
Last Quarter’s Earnings -1.24 Median PE on CY Estimate N/A
Year Ago Earnings -4.58 Next Fiscal Year Estimate -4.637
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 17 17
Mean Estimate -1.11 -1.12 -4.60 -4.64
High Estimates -0.78 -0.78 -3.48 -2.92
Low Estimate -1.40 -1.40 -5.46 -5.84
Coefficient of Variance -14.41 -15.95 -12.96 -18.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 14
OVERWEIGHT 1 1 1
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Beam Therapeutics Inc. - BEAM

Date Name Shares Transaction Value
Feb 21, 2025 Bethany J Cavanagh SVP, Finance and Treasurer 37,527 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $35 per share 1,313,445.00
Feb 20, 2025 Christine Bellon Chief Legal Officer 112,460 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.22 per share 811,961.20
Feb 20, 2025 Christine Bellon Chief Legal Officer 112,968 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $7.22 per share 815,628.96
Feb 20, 2025 Christine Bellon Chief Legal Officer 102,968 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34 per share 3,500,912.00
Feb 20, 2025 Christine Bellon Chief Legal Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 20, 2025 Christine Bellon Chief Legal Officer 10,410 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 4, 2024 Amy Simon Chief Medical Officer 69,553 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $23.76 per share 1,652,579.28
Jul 4, 2024 Amy Simon Chief Medical Officer 68,805 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $22.95 per share 1,579,074.75

Beam Therapeutics Inc. in the News